Application of AP181Ca in hyperkalemia
I. Product Introduction
The AP series resins are pharmaceutical preparations developed and manufactured by Jiangsu Kingshan, complying with all certification and testing standards for pharmaceutical agents. Their primary functions include serving as sustained-release carriers, taste-masking agents, stabilizers, disintegrants, and other key excipients in drug formulations. Specifically, AP181Ca is indicated for the treatment of hyperkalemia.
Mechanism of Action
Calcium polystyrene sulfonate is a special structured resin that is neither digested nor absorbed after oral administration. In the intestinal tract, particularly near the colon, calcium ions within the resin undergo an ion-exchange reaction with potassium ions in the intestinal lumen, binding potassium ions to the resin matrix for excretion in feces and thus reducing serum potassium levels.
II. Core Product Advantages
China's first calcium-type potassium-lowering resin, specifically designed for hyperkalemia in CKD:
· Action Mechanism: Ca²⁺-K⁺ exchange in the intestine, binding 71mg of potassium per gram of resin (exchange capacity ≥ 2.0meq/mL)
· Sodium-Free Safety: No sodium ion release, avoiding sodium-water retention in CKD patients
· Efficient Clearance: 0.3-0.6mm particle size ensures full intestinal coverage, increasing potassium clearance efficiency by 30%
III. Typical Case: Critical Value Management in CKD Stage 5
Patient Profile
· 68-year-old male, eGFR 15mL/min, serum potassium 6.3mmol/L (critical value), with grade 3 hypertension (sodium restriction <2g/day)
Treatment Protocol
Stage | Intervention | Key Data |
Emergency | Oral AP181Ca 30g divided into 3 doses | Serum K⁺ ↓1.0mmol/L within 2h |
Maintenance | 10g/dose, 2 times/day ×7 days | Serum K⁺ stabilized at 4.3mmol/L within 48h |
Safety | No constipation/ileus | Fecal potassium excretion ↑4 times |
IV. Core Clinical Advantage Comparison
Dimension | Traditional Sodium-Type Resin | Kingshan AP181Ca | Advantage Analysis |
Ion Exchange | Na⁺-K⁺ exchange | Ca²⁺-K⁺ exchange | Zero sodium load, protecting heart & kidneys |
Onset Speed | Onset in 6-8 hours | Onset in 2 hours | Suitable for emergency treatment of K⁺>5.5mmol/L |
Intestinal Tolerance | Constipation rate 20% | No related cases | Micron-sized particles reduce mucosal irritation |
V. Simplified Medication Guidelines
1. Indications
· CKD stages 3-5 (eGFR <60mL/min) with serum K⁺ ≥5.0mmol/L
· Priority: Sodium-restricted patients (hypertension/heart failure), intolerant to traditional resins
2. Dosage Schedule
Serum K⁺ (mmol/L) | Initial Dose | Maintenance Dose |
5.0-5.5 | 10g bid | 5-10g qd |
5.6-6.5 | 10g tid | 10g bid |
>6.5 | 30g initial divided dose | 10g tid |
3. Key Considerations
· Take on an empty stomach, 2 hours apart from other medications
· Monitoring: Daily K⁺ in first 3 days, weekly after stabilization (同步监测血钙 monitor calcium simultaneously)
VI. Conclusion
Kingshan AP181Ca provides a "rapid potassium-lowering + long-term safety" solution for hyperkalemia in CKD through calcium-based exchange technology, especially suitable for high-risk sodium-restricted populations. Standardized use effectively controls serum potassium and reduces cardiovascular risks, making it a preferred clinical potassium-lowering option.
